Rapport Therapeutics shareholders approve 2026 votes

Rapport Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on board elections and auditor ratification.

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on board elections and auditor ratification. As of the April 14, 2026 record date, 47,807,623 shares of common stock were outstanding and entitled to vote.

Stockholders elected three Class II directors to serve until the 2029 annual meeting: James Healy, M.D., Ph.D. (41,762,713 votes for and 587,163 withheld), Robert J. Perez (37,592,089 for and 4,757,787 withheld), and Raymond Sanchez, M.D. (41,754,131 for and 595,745 withheld), each with 1,983,035 broker non-votes. Shareholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 44,255,547 votes for, 57,445 against, and 19,919 abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares entitled to vote: 47,807,623 shares Votes for James Healy: 41,762,713 votes Votes for Robert J. Perez: 37,592,089 votes +4 more

7 metrics

Shares entitled to vote 47,807,623 shares Common stock outstanding as of April 14, 2026 record date

Votes for James Healy 41,762,713 votes Election as Class II director at 2026 annual meeting

Votes for Robert J. Perez 37,592,089 votes Election as Class II director at 2026 annual meeting

Votes for Raymond Sanchez 41,754,131 votes Election as Class II director at 2026 annual meeting

Broker non-votes per director 1,983,035 votes Broker non-votes on each Class II director proposal

Votes for PwC ratification 44,255,547 votes Ratification of PwC as independent auditor for 2026

Votes against PwC ratification 57,445 votes Opposing PwC as independent auditor for 2026

Key Terms

Annual Meeting of Stockholders, record date, Class II directors, independent registered public accounting firm, +2 more

6 terms

Annual Meeting of Stockholders financial

"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."

record date financial

"As of the close of business on April 14, 2026, the record date for the Annual Meeting"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

Class II directors financial

"to elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II directors of the Company"

independent registered public accounting firm financial

"to ratify the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

broker non-votes financial

"James Healy, M.D., Ph.D. | | 41,762,713 | | 587,163 | | 1,983,035"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

emerging growth company financial

"Emerging growth company Item 5.07 Submission of Matters to a Vote of Security Holders."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rapport Therapeutics (RAPP) shareholders vote on at the 2026 annual meeting?

Shareholders voted to elect three Class II directors and ratify the company’s independent auditor. The meeting focused on board composition and confirming PricewaterhouseCoopers LLP for the 2026 fiscal year, with detailed vote counts reported for each proposal.

How many Rapport Therapeutics (RAPP) shares were eligible to vote at the 2026 meeting?

A total of 47,807,623 common shares were outstanding and entitled to vote as of April 14, 2026. This record date share count determined which stockholders could participate in electing directors and ratifying the independent registered public accounting firm.

Were the director nominees elected at Rapport Therapeutics’ 2026 annual meeting?

Yes, all three Class II director nominees were elected. James Healy, Robert J. Perez, and Raymond Sanchez each received more votes “for” than “withheld,” and will serve until the 2029 annual meeting or until a successor is duly elected and qualified.

What were the vote results for Rapport Therapeutics’ auditor ratification in 2026?

Shareholders strongly supported ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm, with 44,255,547 votes for, 57,445 against, and 19,919 abstentions. This confirms PwC for the audit of the fiscal year ending December 31, 2026.

What are broker non-votes in Rapport Therapeutics’ 2026 director elections?

Broker non-votes are shares held in street name where the broker did not receive voting instructions on non-routine matters. For each Class II director, there were 1,983,035 broker non-votes, which are counted for quorum but not as “for” or “against.”

How long will the newly elected Rapport Therapeutics Class II directors serve?

The Class II directors elected in 2026 will serve until the 2029 annual meeting of stockholders. Each will continue until a successor is duly elected and qualified, or until earlier death, resignation, or removal under the company’s governance framework.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:12 PM EDT Learn about SEC filing dates

false000201259300020125932026-06-102026-06-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2026

Rapport Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42121	88-0724208
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
99 High Street Suite 2100
Boston, Massachusetts				02110
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 321-8020

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		RAPP		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 10, 2026, Rapport Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 14, 2026, the record date for the Annual Meeting, there were 47,807,623 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2026: (i) to elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II directors of the Company, each to serve until the Company’s 2029 annual meeting of stockholders, and until his respective successor shall have been duly elected and qualified, or until his earlier death, resignation or removal (“Proposal 1”), and (ii) to ratify the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”).

Proposal 1 - Election of Class I Director Nominees

The Company’s stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The results of Proposal 1 were as follows:

Class II Director Nominee		For		Withheld		Broker Non-Votes
James Healy, M.D., Ph.D.		41,762,713		587,163		1,983,035
Robert J. Perez		37,592,089		4,757,787		1,983,035
Raymond Sanchez, M.D.		41,754,131		595,745		1,983,035

Proposal 2 - Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of Proposal 2 were as follows:

For		Against		Abstain
44,255,547		57,445		19,919

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Rapport Therapeutics, Inc.
Date:	June 10, 2026	By:	/s/ Troy Ignelzi
			Troy Ignelzi Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 26.3 KB